Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease

Endocrinology, Diabetes & Metabolism

Lumen A. Mendez Castaner¹  Alessia Fornoni¹  Sebastian Niezen²  Humberto Diaz del Castillo³ 

[1] Katz Family Division of Nephrology and Hypertension University of Miami Miami Florida;School of Medicine Anahuac University Mexico City Mexico;School of Medicine Universidad Autónoma de Guadalajara Guadalajara Mexico;

关键词: antihyperglycaemic agent;    chronic kidney disease;    diabetic kidney disease;    efficacy;    safety;   

DOI  :  10.1002/edm2.72

来源: DOAJ

【 摘 要 】

Abstract Diabetic kidney disease (DKD) is the major contributor to the mortality and the financial burden of diabetes, accounting for approximately 50% of the cases of end‐stage renal disease (ESRD) in the developed world. Several studies have already demonstrated that achieving blood pressure targets in DKD with agents blocking the renin‐angiotensin system confer superior renoprotection when compared to other agents. However, the effects on renal outcomes of antihyperglycaemic agents in these patients have not been reported or studied broadly until recent years. The intent of this article is to review the available data on safety, efficacy, impact on renal outcomes and pathophysiology implications of the most utilized antihyperglycaemic agents in DKD/ESRD.

【 授权许可】

Unknown